VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.